CYRAMZA
Cyramza (ramucirumab) is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated for the treatment of several advanced or metastatic malignancies. It is used to treat patients with gastric or gastro-esophageal junction adenocarcinoma, non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma. The drug is administered either as a single agent or in combination with other therapies, such as paclitaxel, erlotinib, docetaxel, or FOLFIRI, depending on the specific cancer type and prior treatment history. It serves as both a first-line treatment for specific lung cancer mutations and a subsequent therapy for patients who have progressed on earlier treatment regimens.
How CYRAMZA Works
Ramucirumab functions by specifically binding to VEGFR2, which prevents the receptor from interacting with its ligands, including VEGF-A, VEGF-C, and VEGF-D. By blocking these interactions, the drug inhibits the ligand-stimulated activation of the receptor. This process suppresses the proliferation and migration of human endothelial cells. Ultimately, this mechanism inhibits angiogenesis, the formation of new blood vessels that support tumor growth.
Details
- Status
- Prescription
- First Approved
- 2014-04-21
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
CYRAMZA Approval History
What CYRAMZA Treats
5 indicationsCYRAMZA is approved for 5 conditions since its original approval in 2014. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Hepatocellular Carcinoma
CYRAMZA Target & Pathway
ProTarget
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
Pathway Context
VEGFR on blood vessels is activated by VEGF to promote angiogenesis
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
CYRAMZA Competitors
Pro2 other drugs also target VEGFR. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (VEGFR). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to CYRAMZA
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CYRAMZA FDA Label Details
ProIndications & Usage
FDA Label (PDF)CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. in combination with docetaxel, for treatment...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.